Literature DB >> 28028143

ABCA1/ApoE/HDL Pathway Mediates GW3965-Induced Neurorestoration After Stroke.

Xu Cui1, Michael Chopp2, Zhenggang Zhang2, Rongwen Li2, Alex Zacharek2, Julie Landschoot-Ward2, Poornima Venkat2, Jieli Chen2.   

Abstract

BACKGROUND AND
PURPOSE: ATP-binding cassette transporter A1 (ABCA1) is a major reverse cholesterol transporter and plays critical role in the formation of brain high-density lipoprotein (HDL) cholesterol. Apolipoprotein E (ApoE) is the most abundant apolipoprotein and transports cholesterol into cells in brain. ABCA1 and ApoE are upregulated by liver-X receptors. Activation of liver-X receptors has neurorestorative benefit for stroke. The current study investigates whether ABCA1/ApoE/HDL pathway mediates GW3965, a synthetic dual liver-X receptor agonist, induced neurorestoration after stroke.
METHODS: Middle-aged male specific brain ABCA1-deficient (ABCA1-B/-B) and floxed-control (ABCA1fl/fl) mice were subjected to distal middle-cerebral artery occlusion (dMCAo) and gavaged with saline or GW3965 (10 mg/kg) or intracerebral infusion of artificial cerebrospinal fluid or human plasma HDL3 in ABCA1-B/-B stroke mice, starting 24 hours after dMCAo and daily until euthanization 14 days after dMCAo.
RESULTS: No differences in the blood level of total cholesterol and triglyceride and lesion volume were found among the groups. Compared with ABCA1fl/fl ischemic mice, ABCA1-B/-B ischemic mice exhibited impairment functional outcome and decreased ABCA1/ApoE expression and decreased gray/white matter densities in the ischemic boundary zone 14 days after dMCAo. GW3965 treatment of ABCA1fl/fl ischemic mice led to increased brain ABCA1/ApoE expression, concomitantly to increased blood HDL, gray/white matter densities and oligodendrocyte progenitor cell numbers in the ischemic boundary zone, as well as improved functional outcome 14 days after dMCAo. GW3965 treatment had negligible beneficial effects in ABCA1-B/-B ischemic mice. However, intracerebral infusion of human plasma HDL3 significantly attenuated ABCA1-B/-B-induced deficits. In vitro, GW3965 treatment (5 μM) increased ABCA1/synaptophysin level and neurite/axonal outgrowth in primary cortical neurons derived from ABCA1fl/fl embryos, but not in neurons derived from ABCA1-B/-B embryos. HDL treatment (80 μg/mL) attenuated the reduction of neurite/axonal outgrowth in neurons derived from ABCA1-B/-B embryos.
CONCLUSIONS: ABCA1/ApoE/HDL pathway, at least partially, contributes to GW3965-induced neurorestoration after stroke.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  ATP-binding cassette transporter A1; apolipoprotein E; high-density lipoprotein; liver-X receptors; stroke; white matter

Mesh:

Substances:

Year:  2016        PMID: 28028143      PMCID: PMC5263181          DOI: 10.1161/STROKEAHA.116.015592

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  43 in total

1.  Low levels of high density lipoprotein increase the severity of cerebral white matter changes: implications for prevention and treatment of cerebrovascular diseases.

Authors:  M Crisby; L Bronge; L-O Wahlund
Journal:  Curr Alzheimer Res       Date:  2010-09       Impact factor: 3.498

Review 2.  Brain lipoprotein metabolism and its relation to neurodegenerative disease.

Authors:  M Danik; D Champagne; C Petit-Turcotte; U Beffert; J Poirier
Journal:  Crit Rev Neurobiol       Date:  1999

3.  Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels.

Authors:  Liam R Brunham; Janine K Kruit; Terry D Pape; John S Parks; Folkert Kuipers; Michael R Hayden
Journal:  Circ Res       Date:  2006-08-31       Impact factor: 17.367

4.  Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.

Authors:  Xue-Qing Zhang; Orli Even-Or; Xiaoyang Xu; Mariska van Rosmalen; Lucas Lim; Suresh Gadde; Omid C Farokhzad; Edward A Fisher
Journal:  Adv Healthc Mater       Date:  2014-08-22       Impact factor: 9.933

Review 5.  White matter synapses: form, function, and dysfunction.

Authors:  James J P Alix; António Miguel de Jesus Domingues
Journal:  Neurology       Date:  2011-01-25       Impact factor: 9.910

6.  Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death.

Authors:  M Michikawa; K Yanagisawa
Journal:  J Neurochem       Date:  1999-06       Impact factor: 5.372

7.  Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected].

Authors:  Asad Jan; Joanna M Karasinska; Martin H Kang; Willeke de Haan; Piers Ruddle; Achint Kaur; Colum Connolly; Blair R Leavitt; Poul H Sorensen; Michael R Hayden
Journal:  Neurosci Lett       Date:  2015-05-06       Impact factor: 3.046

8.  Behavioral deficits after distal focal cerebral ischemia in mice: Usefulness of adhesive removal test.

Authors:  Thomas Freret; Valentine Bouet; Claire Leconte; Simon Roussel; Laurent Chazalviel; Didier Divoux; Pascale Schumann-Bard; Michel Boulouard
Journal:  Behav Neurosci       Date:  2009-02       Impact factor: 1.912

9.  ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Justin Legleiter; Xianlin Han; John D Fryer; Tomasz Kowalewski; David M Holtzman
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

10.  Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke.

Authors:  Jesús R Morales; Iván Ballesteros; José Manuel Deniz; Olivia Hurtado; José Vivancos; Florentino Nombela; Ignacio Lizasoain; Antonio Castrillo; María A Moro
Journal:  Circulation       Date:  2008-09-15       Impact factor: 29.690

View more
  7 in total

1.  Intermedin Ameliorates Atherosclerosis by Increasing Cholesterol Efflux Through the cAMP-PKA Pathway in Macrophage RAW264.7 Cell Line.

Authors:  Hang Liao; Shixi Wan; Xin Zhang; Di Shi; Xiaojiang Zhu; Xiaoping Chen
Journal:  Med Sci Monit       Date:  2017-11-17

2.  ABCA1/ApoE/HDL Signaling Pathway Facilitates Myelination and Oligodendrogenesis after Stroke.

Authors:  Li Li; Rongwen Li; Alex Zacharek; Fengjie Wang; Julie Landschoot-Ward; Michael Chopp; Jieli Chen; Xu Cui
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

3.  iTRAQ-based proteomic profiling reveals protein alterations after traumatic brain injury and supports thyroxine as a potential treatment.

Authors:  Zhongxiang Zhang; Jiangtao Yu; Pengcheng Wang; Lian Lin; Ruining Liu; Rong Zeng; Haoli Ma; Yan Zhao
Journal:  Mol Brain       Date:  2021-01-27       Impact factor: 4.041

4.  Effect of TO901317 on GF to promote the differentiation of human bone marrow mesenchymal stem cells into dopamine neurons on Parkinson's disease.

Authors:  Miaomiao Li; Junqing Yang; Oumei Cheng; Zhe Peng; Yin Luo; Dongzhi Ran; Yang Yang; Pu Xiang; Haifeng Huang; Xiaodan Tan; Hong Wang
Journal:  Ther Adv Chronic Dis       Date:  2021-03-19       Impact factor: 5.091

5.  Increased protein expression of ABCA1, HMG-CoA reductase, and CYP46A1 induced by garlic and allicin in the brain mouse and astrocytes-isolated from C57BL/6J.

Authors:  Zahra Nazeri; Shirin Azizidoost; Maryam Cheraghzadeh; Asma Mohammadi; Alireza Kheirollah
Journal:  Avicenna J Phytomed       Date:  2021 Sep-Oct

6.  Post-Stroke Administration of L-4F Promotes Neurovascular and White Matter Remodeling in Type-2 Diabetic Stroke Mice.

Authors:  Min Zhou; Rongwen Li; Poornima Venkat; Yu Qian; Michael Chopp; Alex Zacharek; Julie Landschoot-Ward; Brianna Powell; Quan Jiang; Xu Cui
Journal:  Front Neurol       Date:  2022-04-28       Impact factor: 4.003

7.  Administration of Downstream ApoE Attenuates the Adverse Effect of Brain ABCA1 Deficiency on Stroke.

Authors:  Xiaohui Wang; Rongwen Li; Alex Zacharek; Julie Landschoot-Ward; Fengjie Wang; Kuan-Han Hank Wu; Michael Chopp; Jieli Chen; Xu Cui
Journal:  Int J Mol Sci       Date:  2018-10-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.